Cytori recognizes that ‘231
may have value in the long term in areas unrelated to the Company’s
existing product pipeline, and consequently Cytori and the UC Regents
are reviewing their legal alternatives to this ruling, including that of
appealing this decision to the Federal Circuit. It is Cytori’s
intention to aggressively protect its business, its intellectual
property and its investors.
About Cytori
Cytori’s (NASDAQ:CYTX) goal is to be the
global leader in regenerative medicine. The company is dedicated to
providing patients with new options for reconstructive surgery,
developing treatments for cardiovascular disease, and banking patients'
adult stem and regenerative cells. The Celution®
800 System is being introduced in Europe into the reconstructive surgery
market while the Celution® 900 System will be
launched in Japan for cryopreserving a patient's own stem and
regenerative cells. Clinical trials are ongoing in cardiovascular
disease and planned for spinal disc degeneration, gastrointestinal
disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include our
history of operating losses, the need for further financing, regulatory
uncertainties regarding the collection and results of, clinical data,
dependence on third party performance, and other risks and uncertainties
described under the "Risk Factors" in Cytori’s
Securities and Exchange Commission Filings. We assume no responsibility
to update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made.
Media & Investor Contact:
Cytori Therapeutics
Tom Baker,
858-875-5258
tbaker@cytoritx.com
